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Abstract
Introduction: Amyloid-β (Aβ) has been investigated as a diagnostic biomarker and therapeutic drug target. Recent
studies found that cerebrospinal fluid (CSF) Aβ fluctuates over time, including as a diurnal pattern, and increases in
absolute concentration with serial collection. It is currently unknown what effect differences in CSF collection
methodology have on Aβ variability. In this study, we sought to determine the effect of different collection
methodologies on the stability of CSF Aβ concentrations over time.
Methods: Grouped analysis of CSF Aβ levels from multiple industry and academic groups collected by either
lumbar puncture (n=83) or indwelling lumbar catheter (n=178). Participants were either placebo or untreated
subjects from clinical drug trials or observational studies. Participants had CSF collected by lumbar puncture or
lumbar catheter for quantitation of Aβ concentration by enzyme linked immunosorbent assay. Data from all
sponsors was converted to percent of the mean for Aβ40 and Aβ42 for comparison. Repeated measures analysis
of variance was performed to assess for factors affecting the linear rise of Aβ concentrations over time.
Results: Analysis of studies collecting CSF via lumbar catheter revealed tremendous inter-subject variability of Aβ40
and Aβ42 as well as an Aβ diurnal pattern in all of the sponsors’ studies. In contrast, Aβ concentrations from CSF
samples collected at two time points by lumbar puncture showed no significant differences. Repeated measures
analysis of variance found that only time and draw frequency were significantly associated with the slope of linear
rise in Aβ40 and Aβ42 concentrations during the first 6 hours of collection.
Conclusions: Based on our findings, we recommend minimizing the frequency of CSF draws in studies measuring
Aβ levels and keeping the frequency standardized between experimental groups. The Aβ diurnal pattern was noted
in all sponsors’ studies and was not an artifact of study design. Averaging Aβ concentrations at each time point is
recommended to minimize the effect of individual variability. Indwelling lumbar catheters are an invaluable
research tool for following changes in CSF Aβ over 24-48 hours, but factors affecting Aβ concentration such as
linear rise and diurnal variation need to be accounted for in planning study designs.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized by degeneration of neurons and their
synapses leading to progressive cognitive impairment. In
the United States, AD is estimated to be the third lead-
ing cause of death [1] and to have a financial burden on
society comparable with heart disease and cancer [2].
The hallmark of AD at the microscopic level is an over-
abundance in the brain of extracellular plaques formed
by abnormally folded amyloid-beta (Aβ) and intracellular
neurofibrillary tangles of tau. The amyloid hypothesis
proposes that the deposition of Aβ in the brain is a key
first step in AD pathogenesis that precedes the onset of
clinical symptoms by many years [3, 4]. Therefore, Aβ
has been investigated both as a diagnostic biomarker for
amyloid deposition, measured by imaging (e.g. positron
emission tomography imaging with Pittsburgh Com-
pound B (PiB-PET)) or Aβ42 concentration in the cere-
brospinal fluid (CSF) [5], and as a potential therapeutic
target [6, 7].
Previous studies measured Aβ concentrations before
and after amyloid deposition to understand potential
changes in Aβ metabolism during AD pathogenesis. In
these studies, CSF was collected from individuals infre-
quently via lumbar puncture, generally limited to the be-
ginning and the end of the study. The importance of
understanding Aβ metabolism for pharmacologic model-
ing during trials of investigational compounds led to
clinical studies collecting CSF samples repeatedly over
24–48 hours via an indwelling lumbar catheter. A num-
ber of these studies have demonstrated considerable
intra-subject variability in the levels of CSF Aβ [8, 9] and
have also shown a diurnal fluctuation in CSF Aβ that fol-
lows the sleep–wake cycle [10]. This diurnal oscillation
has also been noted in plasma [11]. The frequency and
amount of CSF collected vary greatly in studies employ-
ing indwelling catheters. Differences in CSF collection
methods could be a factor contributing to the observed
variability of Aβ levels. For instance, a recent study
found that CSF sampling frequencies and/or sampling
volume contributes to intra-subject variability in CSF Aβ
levels [12]. Further, sampling hourly via a lumbar cath-
eter has been reported to result in a progressive linear
rise in Aβ concentrations. The cause of the Aβ linear
rise is unknown but is suspected to be due to changes in
CSF flow [10].
Understanding how different collection methodologies
affect the stability of CSF Aβ levels over time is of para-
mount importance for the design of clinical trials, where
these biomarkers would be utilized to study pharmaco-
dynamic activity, and ultimately may determine whether
Aβ has utility in a diagnostic fashion. Several investiga-
tional compounds that target Aβ are currently in clinical
trials [13]. In many cases, particularly in phase I and
early phase II trials, the levels of Aβ in CSF are moni-
tored to assess target engagement. Both lumbar punc-
tures and lumbar catheters are used during clinical trials
to collect CSF. For instance, both plasma and CSF Aβ
levels were monitored in volunteers following treatment
with a gamma-secretase inhibitor [14, 15]. In these stud-
ies, the levels of plasma Aβ were reduced in a dose-
responsive manner, but no significant decreases were ob-
served in the levels of CSF Aβ. In addition, a recent
study examined the levels of CSF Aβ in AD subjects re-
ceiving bapinuzimab, an antibody that targets Aβ. No
changes in the levels of CSF Aβ from baseline were ob-
served following treatment, although there was a de-
crease in the levels of CSF tau [16]. In contrast, subjects
treated with solanezumab, a selective antibody that tar-
gets soluble Aβ, demonstrated a dose-dependent in-
crease in total CSF levels of Aβ40 and Aβ42 [17]. This
increase may be due to downstream effects on Aβ
plaque dissolution. All of these studies collected CSF via
lumbar puncture. Lumbar catheters have also been used
for serial CSF sampling, such as when tracking changes
in Aβ kinetics (i.e. production and clearance) using
stable isotope labeling kinetics [18]. As more therapies
targeting Aβ advance into clinical trials, it is expected
that the use of Aβ and other CSF biomarkers will in-
crease substantially [19].
To identify the most relevant factors that may contrib-
ute to intra-subject variability in CSF Aβ levels, and as
part of the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) consortia, we shared data from multiple clinical
studies on CSF Aβ measurements from placebo or un-
treated subjects and conducted a meta-analysis to identify
factors that may result in changes in CSF Aβ levels. The
combined dataset is the largest collection of participants
with serial CSF sampling via a lumbar catheter (n = 178).
Our results suggest that the slope of the linear rise in CSF
Aβ levels is dependent on the sampling frequency, but
does not affect the hourly variability manifesting as an Aβ
diurnal pattern. The results from this study will help guide
clinical trial design, and provide insight into the relative
stability of proteins associated with AD in CSF.
Materials and methods
Each of the following pharmaceutical research compan-
ies or academic research centers contributed the CSF re-
sults for Aβ isoform x-40 and x-42 concentrations from
assays developed commercially or within the research
centers: Bristol-Myers Squibb (BMS, New York, NY,
USA), AbbVie Inc. (North Chicago, IL, USA), Eli Lilly and
Company (Indianapolis, IN, USA), Merck and Company
(Kenilworth, NJ, USA), Radboud University Medical
Center (Nijmegen, the Netherlands), and Washington
University (St Louis, MO, USA). All of the samples were
obtained via either lumbar puncture or serial sampling
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through an indwelling lumbar catheter. Samples were
obtained from subjects who participated in clinical re-
search studies. Only participants who were given pla-
cebo treatment in pharmacological trials were included
in this study. Table 1 presents information about the
lumbar studies, while Table 2 presents detailed informa-
tion about each study and the demographic information
available for the indwelling catheter studies. Whether or
not study subjects were negative or positive for amyl-
oidosis was known for only one study, and therefore this
variable is not addressed in the analysis. Unless other-
wise noted, the timing of lumbar puncture or lumbar
catheter placement was standardized within a study.
Sleep–wake activity was not monitored before, during,
or after CSF collection.
Methods from Bristol-Myers Squibb serial sampling studies
Subjects and dosing
The clinical phase of the study was conducted from
December 2007 to March 2008 at the California Clinical
Trials Medical Group (Glendale, CA, USA). Healthy
male subjects between 20 and 45 years of age were en-
rolled in the study. This study was conducted using
Good Clinical Practice, as defined by the International
Conference on Harmonization, and in compliance with
the Declaration of Helsinki, and was approved by the
Institutional Review Board of the California Clinical
Trials Medical Group where the study was conducted.
All subjects provided written informed consent prior to
study entry.
Sample collection and assay procedures
For repeated CSF sampling, a 19G Dura-Flex PLUS epi-
dural lumbar catheter (Smiths Medical, Saint Paul, MN,
USA) was placed at the L3/L4 interspace of each subject
approximately 3 hours before dosing. Four CSF samples
of approximately 7–10 ml each were collected in Falcon
polypropylene tubes (BD Biosciences, Franklin Lakes,
NJ, USA) within 2 hours before placebo administration
starting at approximately 7:00 a.m., and then at hourly
intervals for up to 41 hours after dosing. The start time
of CSF collection for all participants was approximately
between 6:30 and 7:30 a.m. Samples of CSF were imme-
diately frozen and stored at or below –80 °C until
shipment to the analytical laboratory (Bristol-Myers
Squibb Bioanalytical Sciences, Princeton, NJ, USA) on
dry ice. Aβ peptide concentrations were determined
using MS6000 human (6E10) Aβ 3-plex kits (Meso Scale
Discovery, Gaithersburg, MD, USA). Samples were ana-
lyzed for concentrations of Aβ38, Aβ40, and Aβ42. The
between-run and within-run coefficient of variation
(CV) for the analytical quality control checks (QCs) for
Aβ38 and Aβ40 concentrations was <25 %, whereas the
between-run CV for the analytical QCs for Aβ42 concen-
tration was >30 %. QCs from Aβ42 were therefore only
evaluated within run and accepted when the within-run
CV was <20 %. All samples for a subject were analyzed in
the same plate or on the same day to minimize the vari-
ability of Aβ42 assessments. In addition, CSF Aβ42 levels
were measured using high-performance liquid chromatog-
raphy (HPLC) as described previously [20].
Methods from AbbVie serial sampling studies
Subjects and dosing
The three AbbVie studies were all conducted at PAR-
EXEL/California Clinical Trials (Glendale, CA, USA). All
three studies were conducted in compliance with the
Declaration of Helsinki and the International Conference
on Harmonization for Good Clinical Practice guidelines.
Institutional review board approval was obtained from
PAREXEL for all three studies and written informed
consent was obtained from all subjects in all three stud-
ies. All subjects were screened to be in good general
health and without neurologic disease. A lumbar cath-
eter was placed immediately before CSF sample collec-
tion started. The subjects were encouraged to stay in
bed, and were allowed free choice of when to sleep
throughout the study. Each study was conducted on a
different group of subjects and each with a different CSF
sampling procedure. There were no subject drop-outs or
refusals. In Study A1, six healthy young men (25–47 years
old) participated, and 5 ml CSF and 4 ml blood were col-
lected from each subject at 0 (6:00 a.m.), 1, 3, 5, 6, 7, 8, 10,
12, 14, 18, 22, and 26 hours. In Study A2, five healthy
older men, two healthy older women (61–74 years old),
and 15 subjects diagnosed with AD (58–83 years old) par-
ticipated. Seven milliliters of CSF and 10 ml blood were
collected from each subject at 0 (5:30 a.m.), 1, 4, 8, 12, 18,
Table 1 Lumbar puncture studies
Sponsor Study Subjects (n) Type of subjects Age (mean (SD)) CSF sample volume per draw (ml)
Lilly L1 19 9 AD, 10 healthy Not obtained Not obtained
L2 10 Healthy 61 (8) 16 ml per draw
L3 34 AD 71.7 (6.4) 10 ml per draw
L4 13 AD 69 (10) 25 ml per draw
L5-A 7 Healthy 52 (6) Not obtained
AD Alzheimer’s disease, CSF cerebrospinal fluid, Lilly Eli Lilly and Company (Indianapolis, IN, USA), SD standard deviation
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and 24 hours. In Study A3, eight healthy young men (24–
45 years old) participated and were divided into two
groups. In one group of four subjects, 6 ml CSF and 4 ml
blood were collected from each subject at 18 time points
over 24 hours (“higher frequency” period) at 0 (8:00 a.m.),
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, and 24
hours. Ten days later, CSF was collected from the same
four subjects at seven time points over 24 hours (“lower
frequency” period) at 0 (8:00 a.m.), 1, 4, 8, 12, 18, and 24
hours. In another group of four subjects, CSF was first col-
lected at lower frequency, followed by higher frequency
CSF collection 10 days later from the same subjects. Dur-
ing each CSF collection in these three studies, the first 2
ml (corresponding to the tubing dead space) were voided.
CSF aliquots of 250 μl were frozen at –80 °C immediately
after collection in 1 ml siliconized polypropylene tubes.
Sample collection and assay procedures
CSF Aβ38, Aβ40, and Aβ42 concentrations were measured
using human Aβ38/Aβ40/Aβ42 multiplex assays (using
6E10 as detection antibody) following the manufacturer’s
procedure (Meso Scale Discovery, Gaithersburg, MD). To
avoid inter-plate variation, all samples from each subject
were measured together in duplicates on the same plate,
and all of the samples from the same study were measured
on the same day. To avoid bias due to intra-plate vari-
ation, all samples from each subject were randomized on
the plate. The means of the intra-plate CVs for the dupli-
cate samples including a control human CSF sample were
<10 %. The means of the inter-plate CVs for the control
human CSF sample were <10 %.
Methods from Lilly lumbar puncture and serial sampling
studies
Subjects and dosing
Eight clinical studies involving CSF sampling for analysis of
Aβ peptides were sponsored by Eli Lilly and Company. De-
tails of collections are presented in Tables 1 and 2. Each
study underwent institutional review board approval and
was conducted in compliance with the Declaration of
Helsinki and the International Conference on Harmoniza-
tion for Good Clinical Practice guidelines. Healthy subjects
participating in each study provided written informed
consent. In studies involving patients with probable AD,
written informed consent was obtained from the subject
as well as their legally authorized representative and their
Table 2 In-dwelling catheter studies
Sponsor Study Subjects (n) Study site Gender (male/female) Age (mean (SD)) CSF sampling volume/frequency
AbbVie A1 6 CCT 6/10 38.2 (9) 8 ml approximately every 2 hours for 24 hours
A2 22 CCT 17/5 68.5 (7.2) 8 ml approximately every 4 hours for 24 hours
A3 8 CCT 8/0 35.3 (8.1) 8 ml approximately every 1 hour for 24 hours;
participants repeated study
BMS B1 10 CCT 10/0 31.6 (6.5) 7 ml every hour for 48 hours
Lilly L6 6 LCRU 60.8 (8.4) 0.1 ml every 1 minute
L7 7 WU 7/0 34 (7) 6 ml every hour for 36 hours
L8 10 PAREXEL 34.6 (8) Volume not obtained; every 1 hour for 10 hours;
every 2 hours for 26 hours
L5-B 2 LCRU 52.7 (4) Volume not obtained; every 1 hour for 10 hours
Merck M1 6 VU 3/3 37.3 (4.6) 0.5 ml every 5 minutes
M2 3 CCT 3/0 26 (7) 6 ml every 1 hour for 8 hours; every 2 hours for 4 hours;
after the last 4 hours
M3 6 CCT 4/2 54.3 (7.9) 4.5 ml every 1 hour for 16 hours; every 2 hours for 10 hours
M4 9 CCT 6/2a 52 (7.8)a 8 ml every 1 hour for 14 hours; every 2 hours for 12 hours
M5 6 CCT 6/0 38.3 (6) 6 ml every 1 hour for 14 hours; every 2 hours for 12 hours
M6 4 SGS 3/1 56.5 (10) Same as M5
M7 4 SGS 2/2 46.5 (10) Same as M5
RUMC R1 12 RUMC 70.3 (7.5) 6 ml every 1 hour for 36 hours
WU W1 57 WU 29/28 60.7 (19) 6 ml every 1 hour for 36 hours
Total 178
aMissing gender and age for one participant
AbbVie AbbVie Inc. (North Chicago, IL, USA), AD Alzheimer’s disease, BMS Bristol-Myers Squibb (New York, NY, USA), CCT California Clinical Trials Medical Group
(Glendale, CA, USA), CSF cerebrospinal fluid, LCRU Lilly Clinical Research Unit (Indianapolis, IN, USA), Lilly Eli Lilly and Company (Indianapolis, IN, USA), Merck Merck
Research Labs (Merck and Company (Kenilworth, NJ, USA); Boston, MA, USA; Upper Gwynedd, PA, USA), Parexel PAREXEL International Early Phase (Los Angeles,
CA, USA), RUMC Radboud University Medical Center (Nijmegen, the Netherlands), SD standard deviation, SGS Clinical Research (Antwerpen, Belgium), VU Vanderbilt
University (Nashville, TN, USA), WU Washington University (St Louis, MO, USA)
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primary caregiver. The diagnosis of probable AD was
based on the National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Association guidelines [21].
Subjects were required to have a Mini-Mental State
Examination (MMSE) score between 14 and 26 inclusive
[22], a Modified Hachinski Ischemic Index score ≤4 [23],
and central nervous system imaging of the brain by com-
puterized tomography scan or magnetic resonance imaging
(MRI) compatible with AD within the past 12 months.
Lilly lumbar puncture studies
Lilly Study 1 was conducted at Indiana University
(Indianapolis, IN, USA) in compliance with the Declar-
ation of Helsinki and the International Conference on
Harmonization for Good Clinical Practice guidelines. In-
stitutional review board approval was obtained from In-
diana University and written informed consent was
obtained from all subjects. The study was designed to
define within-subject variability of CSF Aβ isoforms
from two lumbar punctures taken 1–2 weeks apart from
10 AD patients and nine healthy, age-matched volun-
teers 45 years of age or older (ages ranged from 21 to 84
years old) in the absence of any treatment [24]. Subjects
were ambulatory for 2 hours prior to CSF collection,
which occurred at 2:00 p.m. ± 1 hour. Collected CSF
was immediately aliquoted into polypropylene storage
tubes, quick frozen, and maintained at –70 °C.
Lilly Study 2 was conducted at the Lilly Clinical
Research Unit (Indianapolis, IN, USA) in compliance
with the Declaration of Helsinki and the International
Conference on Harmonization for Good Clinical Practice
guidelines. Institutional review board approval was ob-
tained from Indiana University and written informed
consent was obtained from all subjects. The study was a
single-blind, placebo-controlled, multiple-dose, dose-
escalation study of LY450139 conducted in a combined
inpatient/outpatient fashion [14]. Ten healthy male and
postmenopausal or surgically infertile female volunteers
over 45 years of age (mean ± standard deviation (SD) =
61 ± 8) underwent lumbar puncture using a 25-gauge
needle for CSF sample collection prior to initiation of and
6 hours following 14 ± 1 days of single daily oral adminis-
tration of a placebo treatment. Subjects were ambulatory
(nonrecumbent) for at least 2 hours prior to each lumbar
puncture. A total of 16 ml CSF was incrementally col-
lected as 4 × 4 ml. Each fraction was subsequently
aliquoted into polypropylene cryovials and immediately
frozen. Aliquots were maintained frozen at –70 °C.
Lilly Study 3 was approved by the institutional review
board for each participating site (Oregon Health and
Science University, Portland, OR, USA; Indiana University,
Indianapolis, IN, USA; University of Rochester, Rochester,
NY, USA; California Clinical Trials, Glendale, CA, USA;
Washington University, St Louis, MO, USA; Mayo Clinic,
Rochester, MN, USA). The protocol conformed to the
International Conference on Harmonization guidelines
and to the Declaration of Helsinki. Written informed
consent was obtained from all subjects. The study was a
multisite randomized, double-blind, placebo-controlled
trial also involving LY450139 [25]. Thirty-four subjects
(22 male and 12 postmenopausal female) 50 years or
older (mean age ± SD = 71.7 ± 6.4) with probable mild
to moderate AD underwent lumbar puncture for collec-
tion of CSF prior to and approximately 6 weeks follow-
ing daily oral placebo administration. CSF was collected
approximately 4 hours following the last dose of pla-
cebo. Subjects were ambulatory (nonrecumbent) for at
least 2 hours prior to each lumbar puncture. Approxi-
mately 10 ml CSF was taken at approximately the same
time of day. CSF was collected, mixed by inversion and
aliquoted in polypropylene tubes, frozen, and main-
tained –70 °C until analyzed.
Lilly Study 4 was approved by the institutional re-
view board for each participating site (University of
California (San Diego), San Diego, CA, USA; University of
Pennsylvania, Philadelphia, PA, USA; Oregon Health and
Science University, Portland, OR, USA; Indiana Univer-
sity, Indianapolis, IN, USA; Washington University, St
Louis, MO, USA; University of Washington, Seattle,
WA, USA; Georgetown University, Washington, DC,
USA). The protocol conformed to the International
Conference on Harmonization guidelines and to the
Declaration of Helsinki. Written informed consent was
obtained from all subjects. The study was a multisite, ran-
domized, parallel-arm, placebo-controlled, dose-escalation
trial of LY450139 in mild to moderate AD patients 50
years of age or older (mean ± SD = 69 ± 10) with a treat-
ment duration of approximately 14 weeks [15]. Thirteen
of 15 male and postmenopausal female subjects were ran-
domized to an oral placebo treatment and completed the
study, including successful lumbar puncture for CSF collec-
tion prior to and at the end of the treatment period. Subjects
were ambulatory (nonrecumbent) for at least 2 hours prior
to each lumbar puncture in which 25 ml CSF were obtained
at approximately the same time of day. Results from these
13 individuals are included in the present investigation. CSF
was collected into chilled, polypropylene tubes, rapidly fro-
zen, and maintained at –70 °C until analyzed.
Lilly Study 5-A and Study 5-B were conducted at the
Lilly Research Laboratories Clinic (Indianapolis, IN,
USA). Institutional review board approval was obtained
from Indiana University. The protocol conformed to the
International Conference on Harmonization guidelines
and to the Declaration of Helsinki. Written informed con-
sent was obtained from all subjects. Study 5-A and Study
5-B were two parts of a double-blind, placebo-controlled,
single ascending dose study of LY450139 [26]. In part A,
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seven healthy male and female volunteers 40 years and
older (mean ± SD = 51 ± 5.7) underwent two lumbar
punctures separated by approximately 3 weeks to obtain
CSF 4 hours following oral administration of placebo. In
part B, two healthy subjects participating in part A under-
went indwelling subarachnoid catheterization approxi-
mately 3 weeks after initiating daily placebo administration
to permit serial CSF sampling for 10–12 hours following
the last dose of placebo.
Lilly serial sampling studies
Lilly Study 6 was conducted at the Lilly Clinical
Research Unit. Institutional review board approval was ob-
tained from Indiana University. The protocol conformed
to the International Conference on Harmonization guide-
lines and to the Declaration of Helsinki. Written informed
consent was obtained from all subjects. The study was a
placebo-controlled, single-dose, pharmacokinetic/pharma-
codynamic study of LY450139 in mild to moderate AD pa-
tients and healthy volunteers [27]. Results from six healthy
volunteer subjects over the age of 45 are included in the
present investigation. A single oral dose of placebo was
administered between 9:00 a.m. and 1:00 p.m., approxi-
mately 30 minutes after placement of a sterile indwelling
subarachnoid catheter introduced through the L4/L5
lumbar space and connected to approximately 200 cm of
sterile 1.6 mm ID Tygon tubing positioned in a BioRad
EP-1 peristaltic pump (Bio-Rad Laboratories, Hercules,
CA, USA). CSF was collected at a rate of 0.1 ml/minute
into polypropylene tubes maintained in a refrigerated
Biorad 2110 fraction collector. Initiation of CSF sample
collection occurred approximately 30 and 10 minutes
prior to and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12–14 hours
following oral placebo administration. Individual samples
were immediately aliquoted and frozen after each 2 ml
sample was collected and stored frozen at –70 °C.
Lilly Study 7 was conducted at Washington University.
Institutional review board approval was obtained from
Washington University. The protocol conformed to the
International Conference on Harmonization guidelines
and to the Declaration of Helsinki. Written informed con-
sent was obtained from all subjects. The study was a paral-
lel, double-blind, randomized comparison of the effects of
single oral doses of placebo and LY450139 on the rate of
Aβ formation in seven healthy male volunteers aged 21–
50 years (mean ± SD = 34 ± 7) [18]. CSF was collected via
an indwelling subarachnoid catheter placed at the L3/L4
interspace. CSF sampling occurred at ~7:00 a.m. and con-
tinued hourly for 36 hours during and after intravenous
administration of a stable isotope-labeled amino acid
(13C6-leucine) as described previously [28, 29]. The oral
placebo was administered to seven male subjects. CSF was
frozen and maintained at –80 °C until analyzed.
Lilly Study 8 was conducted at PAREXEL International
Early Phase (Los Angeles, CA, USA). Institutional re-
view board approval was obtained from the California
Institutional Review Board. The protocol conformed to
the International Conference on Harmonization guide-
lines and to the Declaration of Helsinki. Written in-
formed consent was obtained from all subjects. The
study was an investigator-blind, placebo-controlled,
randomized, single-dose design study of LY2811376 in
healthy subjects [30]. Ten of 30 healthy subjects (27
males) aged 21–49 years (mean ± SD = 33 ± 8) partici-
pating in the CSF sampling portion of the study were
administered placebo. The indwelling lumbar catheter
was placed by anesthesiologists 4 hours before oral pla-
cebo administration. Subjects remained supine for the
duration of the CSF sample collection period. Up to 22
CSF samples were collected at regular intervals, from 4
hours before up to 36 hours after study treatment admin-
istration (approximately –4, –2, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 12, 14, 16, 18, 20, 24, 28, 32, and 36 hours relative to
dose administration). CSF samples were collected in poly-
propylene tubes, temporarily stored at –20 °C, aliquoted,
and subsequently maintained at –70 °C until analysis.
Lilly analytical assay methods
For Lilly Study 1, Study 2, Study 3 and Study 6, CSF sam-
ples were analyzed at Eli Lilly and Company (Indianapolis,
IN, USA) using proprietary 96-well plate-format enzyme-
linked immunosorbent assays (ELISAs) developed and val-
idated for measurement of Aβ42 and Aβ40. Coating of
wells with capture monoclonal antibodies provided speci-
ficity for the C-terminal antigenic determinants of Aβ42
(antibody 21F12) and Aβ40 (antibody 2G3). The Aβ spe-
cies recovered from CSF in the two assays were detected
using a biotin-labeled monoclonal antibody raised to an
Aβ N-terminal antigenic determinant (antibody 3D6).
Concentrations of Aβ species were determined by meas-
urement of biotin with horseradish peroxidase-labeled
streptavidin and a colorimetric TMB substrate. The CSF
Aβ42 ELISA provided a dynamic range of 20–250 pg/ml
with intra-assay precision ranging from 2.67 to 3.06
(%CV), and inter-assay precision ranging from 3.61 to
5.28 (%CV). The CSF Aβ40 ELISA provided a dynamic
range of 20–250 pg/ml with intra-assay precision ranging
from 2.97 to 7.53 (%CV), and inter-assay precision ranging
from 3.32 to 7.53 (%CV). CSF ELISAs determined during
analysis of specimens collected from the clinical study
were comparable with those observed during formal valid-
ation of the assays as listed above. For Lilly Study 4, Study
5, and Study 8, this resulted in slightly shifted and broader
dynamic ranges corresponding to 25–400 pg/ml for both
analytes. For Lilly Study 7, CSF Aβ42 and Aβ40 were mea-
sured at Washington University using minor modifications
of the proprietary ELISAs methods described above.
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Methods from Merck serial sampling studies
The seven Merck studies were conducted at three sites,
including Vanderbilt University (Nashville, TN, USA)
PAREXEL/California Clinical Trials (Glendale, CA,
USA) SGS Clinical Research (Antwerpen, Belgium). In-
stitutional review board approval was obtained at each
study site: Vanderbilt University, California Clinical Tri-
als Medical Group, and SGS Clinical Research. The
protocol conformed to the International Conference on
Harmonization guidelines and to the Declaration of
Helsinki. Written informed consent was obtained from
all subjects. All participants were in good general health
and without neurologic disease. After overnight fast,
intra-dermal lidocaine anesthesia was applied prior to
insertion of the spinal needle. Intravenous infusion of
heparinized 5 % dextrose in water was performed to
maintain hydration. A spinal needle was inserted
through either the L2/L3 or the L3/L4 vertebral inter-
space, between 7:00 and 8:00 a.m. After entry into the
subarachnoid space, the intrathecal catheter was secured
externally with adhesive tape. In Studies 1 and 2, the
catheter was extended with silicon tubing attached to a
peristaltic pump with a continuous pump rate of 0.1 ml/
minute for 24 hours in Study 1 and 0.5 ml/minute for
the following 15 hours in Study 2. In Studies 3–7, a 5 ml
syringe was attached to the intrathecal catheter and CSF
was collected by gentle aspiration. The sampling volume
and intervals are presented in Table 2. Each CSF sample,
collected into polypropylene tubes at 4 °C, was frozen on
dry ice within 30–60 minutes of collection for measure-
ment of Aβ peptides. At the completion of sampling, the
catheter was removed and the subject remained recum-
bent for 2 hours and then slowly and progressively moved
to a sitting position over 8 hours. Subjects were observed
for a minimum of 36 hours after cannula removal.
Sample collection and assay procedures
CSF samples from both Study 1 and Study 2 were analyzed
for Aβ40 using an ELISA kit from Biosource International
(Life Technologies, Grand Island, NY, USA) and for Aβ42
using an ELISA kit from Innogenetics NV (Ghent,
Belgium). CSF samples from Studies 3–7 were analyzed for
Aβ peptides using ELISA kits from Meso Scale Discovery
(Gaithersburg, MD).
Methods from Radboud University Medical Center serial
sampling studies and assay procedures
The subject information and methods for serial CSF col-
lection have been described previously [31]. Institutional
review board approval was obtained from Radboud Uni-
versity Nijmegen Medical Center. The protocol conformed
to the International Conference on Harmonization guide-
lines and to the Declaration of Helsinki. Written informed
consent was obtained from all subjects. Six participants
with mild AD (59–85 years, MMSE 16–26) and six
healthy older volunteers (64–77 years) received an intra-
thecal catheter from which 6 ml CSF was collected every
hour for 36 hours. Lumbar catheters were placed between
8:00 and 9:00 a.m. and CSF collection began at 10:00 a.m.
Participant meals and schedules were standardized, but
sleep was not. CSF aliquots were collected in polypropyl-
ene tubes and stored at −80 °C within 30 minutes of draw.
CSF Aβ42 concentrations were determined using the
xMAP-based INNO-BIA assay (Innogenetics NV) and
CSF Aβ40 was determined using an ELISA (The Genetics
Company, Schlieren, Switzerland) according to the manu-
facturer’s specifications. For validation of the results, CSF
Aβ42 was repeated at Merck Research Laboratories
(Kenilworth, NJ, USA) using the same assay, and CSF
Aβ40 and Aβ42 were also repeated using a MSD multiplex
assay Meso Scale Discovery (Gaithersburg, MD).
Methods from Washington University serial sampling
studies and assay procedures
Institutional review board approval was obtained from
Washington University. The protocol conformed to the
International Conference on Harmonization guidelines
and to the Declaration of Helsinki. Written informed con-
sent was obtained from all subjects. Fifty-seven subjects
ranging from age 19 to 84 years were enrolled in the study.
An intrathecal lumbar catheter and an intravenous catheter
were placed between 7:30 and 9:00 a.m. and sample collec-
tion started between 8:00 and 9:30 a.m. for all participants.
Six milliliters of CSF were obtained each hour for 36 hours.
The CSF aliquots were frozen at −80 °C immediately after
collection in 1.7 ml Axygen maximum-recovery polypro-
pylene tubes (Corning, Corning, NY, USA). Participants
were encouraged to stay in bed and were allowed free
choice of when to sleep, read, watch television, use their
laptops, or talk throughout the study. Analysis methods
for Aβ40 and Aβ42 are as described previously [11].
Method of data integration
The data were combined for an integrated analysis of
the lumbar sample studies and from the indwelling cath-
eter studies. Because each study and research group had
different methods of sample collection, volume col-
lected, and ELISAs, the data were transformed to a per-
centage of the mean in order to minimize the effects of
the various extraneous factors. The data transformation
was computed separately for Aβ40 and Aβ42.
It is well known that CSF amyloid concentrations
are log-normally distributed [32] and all sample results
were log-transformed. For the lumbar puncture results,
the difference between the endpoint result and the base-
line result was used as the primary response variable.
For the repeated samples taken over 10–40 hours of
indwelling catheter sampling, the concentrations were
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log-transformed and the mean concentration for each
subject was computed. The difference from the mean
concentration at each sampling time for each subject
was computed. The differences were back-transformed
and multiplied by 100 to obtain the percent concentra-
tion of the mean for each sample. The percent of the
mean was used as the primary response variable.
All statistical programming and analysis was con-
ducted in SAS version 9.1 or higher (SAS Institute Inc.,
Cary, NC, USA). The main statistical method used was
the mixed procedure in SAS.
Analysis of serial sampling during the initial 6 hours
To identify factors relevant to the CSF Aβ increase, CSF
Aβ levels taken within the first 6 hours were analyzed
for each individual. To identify differences in clinical
trial design that may have affected Aβ levels, the data
from Washington University was not included in this
analysis because the same study design was employed
for all of their studies and was the largest dataset (32 %
of total participants). Owing to multiple observations
from each subject, a linear mixed model was used to
analyze the data only from the industry studies. The
subject-specific random effects allow the model to ac-
count for the within-subject correlation. The response
was log-transformed. The model included age group,
number of draws within the first 6 hours, source/com-
panies, and time as covariates. Except for time, all covar-
iates were categorical in nature. There were three age
groups defined as “young” (<30 years old), “medium”
(between the ages of 30 and 50), and “old” (50 years and
older). Similarly, the number of draws within the first 6
hours were also categorized into three levels (groups 1,
2, and 3): group 1 had three draws or less in the first 6
hours, group 2 had greater than three but less than
seven draws in the first 6 hours, and group 3 subjects
had seven draws or more within the first 6 hours. The
data originated from four different sources. Additionally,
an interaction effect between time and number of draws
was considered in the model.
SAS 9.2 was used to analyze the data from the model
specified above. During the analysis we appropriately
choose a covariance structure. The unequal size of the
response vector led us to select the SAS option
“KenwardRoger” as a method for denominator degree of
freedom. The interaction effect and the corresponding
main effects came out as highly significant for both Aβ
isoforms. The normality assumption was also verified
through residual plots.
Analysis of Washington University data
The data consisted of 392 observations from 57 subjects.
The Aβ levels for the first 6 hours were used for the ana-
lysis. Both of the response variables (Aβ40 and Aβ42)
were log-transformed to obtain sufficient symmetry in
their distribution. Two age groups were created, based
on whether a subject was under or over 65 years of age.
Owing to the data being longitudinal I, a linear mixed
model was most appropriate for analysis. The subjects
were used as the block under repeated statement of
mixed procedure of SAS to account for the correlation
of the observations from the same subjects. The model
included the age group and hours after first draw (in-
cluding the 0 hour). The covariance structure was also
chosen appropriately. The normality assumption was
verified through residual plots.
Analysis of CSF diurnal effects on Aβ
All participants from all sponsored studies using in-
dwelling lumbar catheters were including for cosinor
analysis. For each time point, Aβ concentrations for both
Aβ40 and Aβ42 over time were expressed as the percent
of the mean for each individual participant. Average per-
cent of the mean for Aβ40 and Aβ42 was calculated at
each time point for all of each sponsor’s participants.
Owing to variability in study designs within individual
sponsors, the number of samples collected at each time
point is unequal. Cosinor analysis was performed similar
to that described previously [10] except that the linear
rise and cosine transformation were fitted simultan-
eously using the equation:
Y ¼ amplitude  cos 2  pið Þ X=24ð Þ þ acrophaseð Þ
þ slope  X þ bð Þ:
The cosine transformation was applied to the time
variable using 24 hours as the default circadian cycle.
Graphpad Prism version 6.0b for Mac (Graphpad Soft-
ware, San Diego, CA, USA) was used to estimate the
parameters of the circadian patterns for Aβ40 and
Aβ42. The mesor (midline of the oscillation), ampli-
tude (distance between the peak and mesor), and acro-
phase (the time corresponding to the peak of the curve)
were calculated for each group. Note, the y-intercept, b, is
equal to the mesor in the above equation.
Results
Indwelling catheter findings
Variability of Aβ concentration
Variability in the concentration of Aβ40 and Aβ42 was
found in the untreated and placebo-treated subjects en-
rolled in 16 separate serial CSF sampling studies
(Table 2). Both Aβ42 and Aβ40 concentrations exhibited
marked variability as a function of time (Figs. 1 and 2).
A gradual upward drift was generally noted for both
analytes and the observed increases did not return to
baseline at 24 hours or even after extended sampling for
as long as 36 hours.
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A distinctly different pattern was observed in one ser-
ial CSF sampling study characterized by a sharp increase
in Aβ40 and Aβ42 concentrations immediately after initi-
ation of sample collection and followed by a rapidly
achieved plateau that was sustained through the remaining
sample collection (Figs. 1e and 2e). In this one study, a
bacterial filter was incorporated into the sample collection
device and was shown to interact with CSF Aβ40 and
Aβ42 concentrations recovered from the sample matrix
during the first 6 hours of collection, as reported previ-
ously [31]. As a result of this methodological difference,
data from this one study (Radboud University Medical
Center) were not included in all subsequent data analyses.
Previous work has shown that Aβ40 and Aβ42 con-
centrations vary with the sleep–wake cycle [10]. Cosinor
analysis was used to compare circadian patterns of CSF
Aβ dynamics from all of the studies with serial CSF sam-
pling. The sleep–wake cycle was not monitored in these
participants and could not be incorporated into the ana-
lysis. There were two sponsors with a large number of
participants who underwent similar clinical trial designs
in terms of frequency of CSF draws. The seven Merck
studies (M1–M7) involved 38 participants (mean age
44.2 years, SD 11.2). The second study from Washington
University included 57 subjects (mean age 60.7 years, SD
19). In both studies, CSF draws were taken approximately
every 1–2 hours for 24–36 hours. Fig. 3 shows the simul-
taneous fit of the linear rise and cosine transformation to
the mean-adjusted group average (percent of mean) data
for the Merck and Washington University studies. Both
Aβ40 and Aβ42 showed significant cosinor fits for both
studies compared with a straight line (p <0.0001 for all
analytes). Further, the 95 % confidence intervals for ampli-
tude do not cross zero for both sets of studies (Fig. 3). The
slope of the linear rise is also similar for both Aβ40 and
Aβ42. The amplitude of the Merck studies is higher
than that seen in the Washington University data, a dif-
ference possibly attributable to an overall younger
population. Finally, the amplitude peaks occurred at ap-
proximately 20:00–21:00 p.m. in both studies and for
both Aβ40 and Aβ42.
We also performed cosinor analysis on the mean-
adjusted group average (percent of mean) data from three
additional sponsors: AbbVie, BMS, and Lilly (Fig. 4). Des-
pite variability in study design, numbers of participants,
and sampling at each time point, studies from all sponsors
showed a cosine fit for Aβ40 concentrations and all but
AbbVie studies showed a cosine fit for Aβ42 concentra-
tions. Peak amplitude showed greater variability in these
three studies and occurred at different times of day,
Fig. 1 Profile of percent change of the mean in Aβ42 for each subject studied by each sponsor with serial sampling of CSF for up to 40 hours post
catheter placement. Percent change of the mean is on the y axis and time of day for each study sponsor is shown on the x axis. a AbbVie Inc.,
b Bristol-Myers Squibb (BMS), c Eli Lilly and Company, d Merck and Company, e Radboud University Medical Center (RUMC), f Washington University
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although the time was the same for Aβ40 and Aβ42
within each study sponsor. AbbVie studies had similar
peak times for both Aβ40 and Aβ42 compared with the
Merck and Washington University studies (21:00–22:00
p.m.). Both the Lilly and BMS studies had earlier peak
times. For the Lilly studies, this may be due to an overall
earlier start time: the Lilly studies began CSF collection
as early as 02:00 a.m. and had a peak time of 16:00 p.m.
for both Aβ40 and Aβ42. An earlier start time, however,
does not account for the BMS studies that began CSF
collection at 06:00 a.m. and had a peak time of 13:00–
14:00 p.m. Differences in participant sleep–wake activ-
ity are unknown for all studies; therefore we cannot
account for changes in sleep–wake patterns between
studies that may correlate with differences in peak
times. BMS was found to have the highest amplitude
and slope for Aβ40 and Aβ42, but also had the youngest
participants (mean age 31.6 years, SD 6.5) compared
with Merck, Washington University, AbbVie (mean age
55.8 years, SD 17.8), or Lilly (mean age 42.4 years, SD
14.3) studies.
Please see Additional file 1 for the graphs from Figs. 3
and 4 with standard error of the mean intervals.
Linear rise in Aβ concentration
Statistical analysis was performed to identify factors that
were significantly associated with the change in increas-
ing linear trend for both Aβ40 and Aβ42 over time. We
analyzed the slope of the Aβ increase over the first 6
hours relative to the number of CSF draws made during
that time period. Since the studies differed in duration,
only the first 6 hours were used in the analysis. The in-
crease appeared to be the most dramatic during this
time period. Factors such as age group, gender, ethnicity,
frequency of draws, sponsor, and time were analyzed.
For this analysis, subjects were divided into three age
groups defined as “young” (<30 years old), “medium”
(between the ages of 30 and 50), and “old” (50 years and
older). Similarly, the number of draws within the first 6
hours were also categorized into three levels (groups 1, 2
and 3): group 1 had three draws or less in the first 6
hours, group 2 had greater than three but less than
seven draws in the first 6 hours, and group 3 subjects
had seven draws or more within the first 6 hours.
Of these factors, only the frequency of the CSF draw,
time, and the interaction of draw frequency and time were
significant (Table 3). The repeated-measures analysis (or
Fig. 2 Profile of percent change of the mean in Aβ40 for each subject studied by each sponsor with serial sampling of CSF for up to 40
hours post catheter placement. Percent change of the mean is on the y axis and time of day for each study sponsor is shown on the x axis.
a AbbVie Inc., b Bristol-Myers Squibb (BMS), c Eli Lilly and Company, d Merck and Company, e Radboud University Medical Center (RUMC),
f Washington University
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linear mixed model), described in Materials and methods,
showed that the interaction effects of the number of draws
relative to time were significant for both Aβ40 and Aβ42.
We further obtained the estimates of the slope of time
within each draw group. All of the estimates were posi-
tively associated with the frequency of CSF draws. Further
analysis revealed that the slope over time for draw groups
3 differed significantly from zero (Table 4), indicating that
more frequent CSF draws resulted in a larger slope. Sev-
eral factors were not known for the majority of the studies,
most importantly amyloid status and sleep parameters that
may affect the slope of the linear rise.
Age was not a significant factor for the combined data.
In the industry studies, however, only 15 out of the 107
subjects (minus the RUMC data) were older than 65 years.
In contrast, 36 out of 57 subjects in the Washington
University dataset were older than 65 years. Analysis of
this dataset alone showed a trend towards an effect of age
on the rise in Aβ levels in the first 6 hours. Younger sub-
jects showed a greater change in Aβ42 levels over time
relative to older subjects (p = 0.02); however, for Aβ40
there was no significant difference between the age groups
in terms of the change in Aβ levels in the first 6 hours
(p value = 0.17). Again, this difference between age groups
and Aβ isoforms may be due to amyloid deposition, a
factor not included in this analysis.
Lumbar puncture findings
For untreated or placebo-treated subjects enrolled in
four separate clinical studies, intra-subject variability for
CSF Aβ40 and Aβ42 collected by lumbar puncture were
generally stable on comparison between baseline and
endpoint sampling scheduled approximately 2 weeks
apart. Occasionally, individuals exhibited notable shifts
from baseline (increase or decrease); however, the major-
ity of subjects exhibited stable results. Within individual
studies, lumbar punctures were performed at approxi-
mately the same time of day. Overall, no significance dif-
ference between the endpoint and baseline for Aβ42 and
Aβ40 was observed (p = 0.54 and p = 0.14 respectively)
(Fig. 5a,b). In addition, Aβ40 and Aβ42 results for indi-
vidual samples were highly correlated (r = 0.8; p <0.001).
Discussion
We examined CSF Aβ40 and Aβ42 concentrations across
multiple studies from four different companies and two
academic institutions. While a tremendous amount of
inter-individual variability existed, a general pattern of rap-
idly increasing concentrations of Aβ40 and Aβ42 in the
first 12 hours of a study was found across all subjects in
all indwelling lumbar catheter studies; in some cases,
Aβ40 and Aβ42 reached levels as high as 200 % from the
initial baseline draw. In most of the subjects, the slope of
Fig. 3 Diurnal oscillation of Aβ peptides in participants from two different study cohorts. Data presented as mean-adjusted average Aβ levels of
the group over time of day for all subjects. Data from Merck and Company for (a) Aβ40 and (b) Aβ42, and data from Washington University for
(c) Aβ40 and (d) Aβ42. Mesor-to-peak amplitudes of diurnal fluctuation of Aβ40 were 5.48 % for Merck and 4.91 % for Washington University.
Mesor-to-peak amplitudes of diurnal fluctuation of Aβ42 were 4.87 % for Merck and 4.26 % for Washington University. The cosine transformation
for all datasets was significantly different from a straight line (all p <0.0001). CI confidence interval
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the linear rise decreased after the first 24 hours, but the
levels did not return to baseline by 24 hours. Our results
suggest that the use of indwelling catheters to collect mul-
tiple CSF samples results in an upward drift in the levels
of both Aβ40 and Aβ42 relative to the initial draw. In con-
trast, the levels of Aβ40 and Aβ42 did not change signifi-
cantly from baseline to second draw when samples were
taken by lumbar puncture performed at a similar time of
the day 2 weeks apart.
The tremendous inter-subject variability of Aβ40 and
Aβ42 seen over time could influence the results of AD
prevention studies that target Aβ. Averaging Aβ concen-
trations at each time point is recommended to minimize
the effect of individual variability and distinguish effects
between experimental groups. We further recommend
managing this variability by calculating the area under the
curve using pharmacokinetic–pharmacodynamic models.
For example, a previous study of a gamma-secretase in-
hibitor was able to show relatively small effects on Aβ in
CSF collected via indwelling lumbar catheters using this
technique [18].
A circadian rhythm is a cyclic oscillation intrinsic to
many biologic processes, such as body temperature and
hormone levels, and is typically studied using cosinor
analysis to fit a cosine transformation with a 24-hour
period. Aβ concentrations have been found to fluctuate
over time in several studies collecting CSF via a lumbar
catheter [8, 9]. Further, a previous study correlated
Fig. 4 Diurnal oscillation of Aβ peptides in participants from three different study cohorts. Data presented as mean-adjusted average Aβ levels of
the group over time of day for all subjects. Data from AbbVie Inc. for (a) Aβ40 and (b) Aβ42, from Bristol-Myers Squibb (BMS) for (c) Aβ40 and
(d) Aβ42, and from Eli Lilly and Company for (e) Aβ40 and (f) Aβ42. Mesor-to-peak amplitudes of diurnal fluctuation of Aβ40 were 4.61 %
(AbbVie), –6.52 % (BMS), and –4.90 % (Lilly). Mesor-to-peak amplitudes of diurnal fluctuation of Aβ42 were 4.29 % (AbbVie), –7.01 % (BMS),
and –5.34 % (Lilly). The cosine transformation for all datasets were significantly different from a straight line except for Aβ42 from the AbbVie
studies (p = 0.06). CI confidence interval
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fluctuating CSF Aβ levels to the sleep–wake cycle (i.e. a
diurnal pattern) in healthy young normal control subjects
and older adults more than 60 years old with and without
amyloid deposition [10]. In that study, younger controls
demonstrated much higher amplitude of Aβ oscillation as
compared with amyloid-positive or amyloid-negative older
adults.
Despite heterogeneity in the frequency of CSF collec-
tion in this study, we found evidence in data from all
sponsors for a diurnal pattern of both Aβ40 and Aβ42.
The only exception was the AbbVie data for Aβ42 which
showed a mesor-to-peak amplitude of 4.29 % with 95 %
confidence intervals that do not cross zero (0.71–7.87)
suggesting a cosinor fit, but only a trend toward a differ-
ence with a straight line was noted (p = 0.06). This dis-
crepancy is attributable to both the scatter of the data
points in the first and last 6 hours of sampling due to CSF
collection occurring at slightly different times of day
across the AbbVie studies and a limited sampling time of
24 hours, the shortest period among all of the sponsors.
Prior work analyzed a smaller group of subjects from the
AbbVie studies (n = 21 compared with n = 36 in our ana-
lysis) and reported that intra-subject variability was related
to sampling frequency and/or sampling volume [12]. We
suspect a diurnal oscillation was not seen in this prior
work because each study was analyzed separately (n = 6–
8/study) and not as a larger pooled analysis.
Cosinor parameters, such as amplitude, differed across
all studies. Aβ40 and Aβ42 showed similar oscillations
within study sponsor, but not between all study spon-
sors. The peak-to-trough amplitude fluctuations of Aβ40
and Aβ42 varied between sponsors from approximately
8.52 to 14.02 % per 24 hours. The peak time of Aβ levels
also varied between study sponsors. For example, both
the Merck and Washington University datasets were
found to have Aβ levels peak at roughly 13–14 hours
after the collection was started (which is equivalent to
~20:00–21:00 p.m.). BMS, however, peaked earlier for
both Aβ40 and Aβ42 at approximately 8 hours after col-
lection started (14:00 p.m.). In contrast, Aβ40 and Aβ42
peaked at approximately 14 hours after collection started
in the Lilly studies (16:00 p.m.) and at approximately
16–17 hours after collection started in the AbbVie stud-
ies (21:00–22:00 p.m.).
These discrepancies in the amplitudes and peak time of
CSF Aβ fluctuation are possibly due to differences in par-
ticipant ages, sample collection schedules, analytic tech-
niques used between sites, participant stress levels,
participant amyloid status, and differences in sleep–wake
activity between participants in the different groups. Our
findings suggest that the Aβ diurnal pattern is not a time-
keeper that directly interacts with the circadian clock, but
is dependent on human processes with a diurnal pattern—
such as changes in neuronal activity with the sleep–wake
cycle as described previously [10, 33]—and may be modifi-
able [34]. The timing and amount of participant sleep as
well as light exposure were not monitored in these studies;
therefore we cannot test our hypothesis that differences in
sleep–wake activity accounts for the inter-study difference
in Aβ oscillation. However, the finding of an Aβ diurnal
pattern for both Aβ40 and Aβ42 despite study heterogen-
eity and other confounders strongly suggests that this oscil-
lation is due to an intrinsic human biological process
rather than an artifact of experimental design.
Since the studies enrolled subjects of different demo-
graphics and different protocols were employed for CSF
collection across the studies, statistical analysis was con-
ducted to identify factors that were associated with the
rise in Aβ levels. Factors such as age, gender, clinical
sponsor, and frequency of CSF draws were all analyzed.
In the industry-sponsored studies, where considerable
variability existed in the CSF collection designs, the fre-
quency of CSF draws was significantly associated with
the Aβ rise. The results indicated that performing more
Table 3 ANOVA of fixed effects for industry in-dwelling catheter studies for Aβ40 and Aβ42
Aβ40 Aβ42
Effect F value (df1, df2) p value F value (df1, df2) p value
Age group 0.78 (2,156) 0.46 1.75 (2, 38.5) 0.19
Draw group 9.76 (2, 62.3) 0.0002* 11.07 (2, 15.1) 0.001*
Sponsor 0.94 (3, 137) 0.42 0.85 (3, 112) 0.47
Time 23.3 (1, 145) <0.0001* 19.66 (1, 43.7) <0.0001*
Time × draw group 11.55 (2, 139) <0.0001* 8.5 (2, 22.3) 0.0018*
ANOVA analysis of variance, df degrees of freedom
*p < 0.05
Table 4 Slope and significance for time × draw groups 1–3
interaction for Aβ40 and Aβ42
Aβ40 Aβ42
Time × draw group Slope p value Slope p value
1 0.41 0.56 1.02 0.25
2 1.6 0.12 0.79 0.45
3 4.12 <0.001* 4.32 <0.001*
*p < 0.05
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than seven CSF draws in the first 6 hours of the study
had a large effect on the rise in CSF Aβ, while the rise in
CSF Aβ was largely not evident in studies that collected
six or less draws in the first 6 hours. This finding is simi-
lar to previous reports from AbbVie that sampling fre-
quency was a factor in the Aβ linear rise [12]. Several of
the same studies sponsored by AbbVie are included in
this analysis, but our study includes additional industry
and academic sponsors and shows the same effect.
The Aβ linear rise is not a diurnal effect and is most
probably a consequence of frequent CSF draws via an in-
dwelling lumbar catheter leading to a shift in the rostro-
caudal dynamics in CSF. A recent study showed that
levels of Aβ were higher in CSF collected from the cisterna
in patients suffering from trigeminal neuralgia relative to
CSF from lumbar draws taken from patients suffering
from tension-type headaches [35]. Potentially, frequent
CSF draws from the lumbar region could result in an in-
crease in the flow of CSF from the cisterna to the lumbar
region, where Aβ levels may be higher. The volume of
CSF collected may also be involved, although we could
not address this question because all but one study (Study
M3, n = 6; Table 2) collected 6–8 ml/draw. Factors that
affect the concentration of Aβ40 and Aβ42 may also be in-
volved in the linear rise. For instance, previous work has
shown attenuation in the linear rise of Aβ42 in amyloid-
positive individuals [10]. Studies that involve different CSF
collection protocols and labeling of CSF Aβ may help to
address this question [36].
The studies conducted at Washington University in St
Louis enrolled subjects in different age groups. In these
studies, there was a trend towards age being a significant
factor for the rise in CSF Aβ levels, with younger subjects
showing significantly higher increases relative to older sub-
jects for Aβ42. Previous studies examining age and the rise
in CSF Aβ levels did not show an effect in amyloid-negative
subjects [10]. However, in that study, the rise in Aβ was cal-
culated over a 24-hour period, rather than the first 6 hours.
In addition, subjects that were amyloid-positive did display
smaller increases in CSF Aβ levels over time.
Implications for future clinical trial design
The issue concerning whether or not significant fluctua-
tions in CSF Aβ concentrations occur owing to CSF col-
lection methodology is of paramount importance for the
design of clinical trials where these biomarkers would be
utilized to study pharmacodynamic activity, and ultimately
may determine whether these biomarkers have utility in a
diagnostic fashion. Further, the use of a filter system in the
sampling setup employed by RUMC illustrates that the se-
lection of sampling materials and the configuration of
those materials on the recovery of Aβ species from CSF
pulled through catheter systems needs to be carefully eval-
uated. Overall, our analysis has identified that frequency
of CSF draws and age are factors that contribute to the
linear rise in Aβ levels. The Aβ diurnal pattern, in con-
trast, is suggested to be an intrinsic process that occurs in-
dependent of CSF collection methodology. These findings
are important for the design of studies of Aβ. For instance,
a recent trial investigated whether sleep deprivation re-
sulted in an increase in CSF Aβ concentration [34]. The
study did show an increase in the Aβ42 concentration in
the sleep-deprived group compared with the normal sleep
control group, but Aβ40 did not show the same pattern as
Aβ42. This is in contrast to our results that show Aβ40
and Aβ42 oscillating together. The sleep-deprived group
had an additional four CSF collection time points between
hours 5 and 13 that complicate the study interpretation
because differences in CSF collection may account for the
rise in CSF Aβ42 concentration and discordance with
Aβ40, although additional analyses of total protein showed
that there was no effect of the differential sampling on
CSF protein concentration between the two groups.
Fig. 5 Profile plot of cerebrospinal fluid (CSF) (a) Aβ40 and (b) Aβ
42 from subjects in Lilly lumbar puncture studies given placebo for
approximately 2 weeks with lumbar punctures obtained at baseline
and endpoint
Lucey et al. Alzheimer's Research & Therapy  (2015) 7:53 Page 14 of 17
From our analysis, it is recommended that the frequency
of CSF draws should kept to no more than 1/hour with a
volume of 6–8 ml in order to minimize changes in CSF
Aβ with frequent draws, particularly in the first 6 hours of
collection; also, it is critical that a standard draw frequency
be utilized across all study groups. Our data are not suffi-
cient to determine whether these are the optimal CSF
draw volume and frequency to control for the linear rise.
Further, the linear rise needs to be accounted for during
analysis of Aβ levels in CSF collected by indwelling lum-
bar catheters either by fitting both a cosine function
and linear rise simultaneously as we have done, or by
subtracting out the linear rise before cosinor analysis as
reported previously [10].
Conclusion
Indwelling lumbar catheters are an invaluable research
tool for following changes in CSF Aβ over 24–48 hours,
but factors affecting Aβ concentration such as linear rise
and diurnal variation need to be accounted for in plan-
ning study designs.
Additional file
Additional file 1: Figure S1. Shows plots of cosinor analysis of data
from all sponsors as in Figs. 3 and 4 with standard error of the mean
intervals shown.
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